Chondroitin sulfate-functionalized lipid nanoreservoirs: a novel cartilage-targeting approach for intra-articular delivery of cassic acid for osteoarthritis treatment

Heba M. K. Ebada, Maha M. A. Nasra, Rasha A. Nassra and Ossama Y. Abdallah

Central Lab, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt; Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt; Department of Medical Biochemistry, Faculty of Medicine, Alexandria University, Alexandria, Egypt

ABSTRACT

Novel intra-articular nanoreservoirs were implemented employing different cartilage targeting approaches to improve cartilage bioavailability of a chondroprotective drug, cassic acid (CA), for effective amelioration of cartilage deterioration off-targeting CA gastrointestinal disorders. Herein, we compared active cartilage-targeting approach via chondroitin sulfate (CHS) functionalization versus passive targeting using positively charged nanoparticles to target negatively charged cartilage matrix. Firstly, CA integrated nanoreservoirs (CA-NRs) were fabricated based on ionic conjugation between CA and cationic hydrophobic surface modifier octadecylamine (ODA) and were further functionalized with CHS to develop CHS-CA-NRs. Confocal laser microscope was used to visualize the accumulation of nanoparticles into the cartilage tissue. Both targeting approaches promoted CA local cartilage availability and prolonged its residence time. Compared to passive targeted CA-NRs, active targeted CHS-CA-NRs showed higher fluorescence signals in proximity to and inside chondrocytes which lasted for up to 21 days. In MIA-osteoarthritic rats, CHS-CA-NRs showed superior antiosteoarthritic activity, exhibiting highest cartilage repair compared to CA-NRs. Additionally, CHS-CA-NRs significantly inhibited OA inflammatory cytokine, degradation enzyme and oxidative stress and improved cartilage matrix biosynthesis. Conclusively, CHS-CA-NRs improved OA repair showing a superior efficacy for articular cartilage targeting with CHS which could be a potential advance for OA therapy.

1. Introduction

Osteoarthritis (OA), a complex disease affecting multiple joint architectures, is characterized by cartilage deterioration and synovium inflammation causing impaired movement of the elderly (van den Bosch 2020; Peng et al. 2021; Jansen & Mastbergen 2022). OA therapy attempts failure arose from a shortage in delivery of antiosteoarthritic drugs to their target site inside the joint, to be able to modify the progression, and treat the structural changes associated with OA while avoiding systemic poor bioavailability and/or associated side effects (Latourte et al. 2020; Morales & Irlandini 2022). Intra-articular (IA) therapy is considered as an appropriate route to localize antiosteoarthritic drugs into the arthritic joint thus minimizing systemic toxicity (Brown et al. 2019; Migliore et al. 2020). Nevertheless, IA delivery systems should overcome the environmental obstacles such as poor cartilage penetration, and rapid clearance that shortens the intra-articular residence time (Liang et al. 2021; Mancipe Castro et al. 2021). Thus, using nanoparticles to target the drug inside the cartilage tissue, the primary site for OA process, is a promising approach (Bedingfield et al. 2021; Mancipe Castro et al. 2021). Cartilage-targeting nanomaterials offer advantages for OA therapy through different strategies for cartilage-targeting; (1) passive targeting that is related to nanoparticles physicochemical properties including size, charge and shape, and (2) active targeting that is governed by decoration of nanoparticles with specific moieties that bind to unique receptors on cartilage matrix or chondrocytes. The most prevalent approach for passive targeting relies on employing positively charged nanoparticles that electrostatically interacted with negatively charged glycosaminoglycans (GAGs), forming the cartilage matrix (Xiao et al. 2021; He et al. 2022). For active cartilage-targeting, it is linked to functionalization of the particles with moieties like chondroitin sulfate (CHS), and type II collagen (Col2)-binding peptides that have potential affinity to specific receptors on the cartilage matrix or on the chondrocytes (Maudens et al. 2018; Brown et al. 2020; Bedingfield et al. 2021).

CHS, a natural anionic glycosaminoglycan, has substantial targeting potential toward human articular cartilage thanks
to its interaction with Col2, scavenger receptor CD36 and other receptors on chondrocytes (Sobal et al. 2013, 2016). Therefore, CHS decorated drug delivery carriers promote articular cartilage uptake compared to non-functionalized particles turning the cartilage into a drug reservoir for sustained intra-tissue delivery (Jain et al. 2014; Yin et al. 2017). Additionally, CHS is one of the natural cartilage matrix components and inherently possesses anti-inflammatory and anti-osteoarthritic activity making it an approved dietary supplement in USA and Europe (Reginster & Veronese 2021).

Cassic acid, also known as rhein (4,5-dihydroxyanthraquinone-2-carboxylic acid, CA), is a natural agent belonging to anthraquinones and found in rhubarb (Cassia reticulate, Rheum palmatum and Rheum undulatum), and has widespread uses in Chinese medicine (Wang et al. 2020; Li et al. 2021). Since the early 1990s, the diacetyl pro-drug of CA called diacerein (DCN) has received a great clinical appreciation in OA treatment by halting inflammation and repairing the existing cartilage destruction (Almezgagi et al. 2020). CA role in molecular targeting of interleukins inhibition, superoxide anion reduction, and cartilage matrix metalloproteinases suppression mechanisms that anticipated in OA pathophysiology was extensively investigated on human OA cartilage explants (Moldovan et al. 2000), murine osteoclasts (Boileau et al. 2008), and bovine chondrocytes (Martin et al. 2003). Moreover, CA could restore the OA catabolic/anabolic imbalance by improving cartilage matrix biosynthesis (Schöngen et al. 1988).

Otherwise, in 2013, oral DCN was recalled according to European Medicines Agency (EMA) owing to its associated gastrointestinal disorders (diarrhea) (Sun et al. 2016). Afterwards, in 2014, EMA announced that DCN’s therapeutic benefits outweighed its side effects and specifically recommended the discontinuation of DCN therapy when severe diarrhea occurs (Almezgagi et al. 2020). However, DCN exhibited low bioavailability ascribed to its low aqueous solubility concomitant to malabsorption properties, so different DCN-nanosystems were developed to enhance its bioavailability (Jain et al. 2013; Allam et al. 2017). Yet, few studies reported that IA administration of the pro-drug form (DCN) improved cartilage repair and inhibited inflammation in rats (Jung et al. 2020; Eladawy et al. 2021). However, the extent of DCN intra-articular metabolism hasn’t been investigated which might result in inter-subject variation. In this context, CA represents an ideal chondroprotective drug for OA therapy through IA delivery. So far, no work has assessed the biological efficacy of CA through IA application, despite works that aimed at developing CA loaded PLGA microparticles (Gómez-Gaete et al. 2017) and PLGA nanoparticles (Hu et al. 2020) for IA administration.

2. Materials and methods

2.1. Materials

Cassic acid was acquired from Nutragreenlife Biotechnology, India. Chondroitin sulfate and Octadecylamine were acquired from Sigma-Aldrich, USA. Compriitol 888 ATO, Glyceryl mono-stearate, Precirol ATO 5, Gelucire 39/01 and Stearic acid were received from Gattefosse, France. Pluronic F-127 was obtained from BASF, Germany. Monoiodoacetate sodium 99% was purchase from ACROS Organics, Belgium.

2.2. Apparent lipid solubility

CA apparent solubility in different solid lipids (preciprol ATO 5, compriitol 888 ATO, glyceryl monostearate, stearic acid, and gelucire 39/01) was assigned using a melt-solubilization technique (Kaur et al. 2017). Briefly, the lipid was added in increments of 0.5 g–5 mg of CA placed in a vial with consistent heating at 5 ºC above the melting temperature of respective lipids in a shaker incubator. The least lipid amount that could solubilize CA was determined as CA lipid solubility.
2.3. Preparation of castic acid–octadecylamine (CA-ODA) conjugate

CA-ODA conjugates were prepared at different molar ratios (1:1, 1:2, and 1:3) by adding CA (10 mg) in increments to 10 mL methanolic solution of ODA under stirring until a clear mixture was obtained. The stirring was extended for 2 h at 25 °C and methanol was then vacuum-evaporated.

2.4. CA-ODA conjugate characterization

2.4.1. Fourier transform-infrared (FT-IR)

FT-IR spectrum of CA, ODA, and CA-ODA conjugates were scanned between 700–4000 cm⁻¹ using FTIR spectrometer (Cary 630, Agilent, USA).

2.4.2. Partition coefficient (Po/w) determination

1 mL water (pre-saturated by n-octanol) was added to 1 mL of saturated n-octanol (pre-saturated by water) of CA and CA-ODA conjugates. The samples were agitated at 25 °C for 24 h, and then allowed to stand for 24 h. CA solubility was spectrophotometrically determined at 258 nm. The oil/water partition coefficient (Po/w) was calculated from Equation 1:

\[ P_{o/w} = \frac{C_n}{C_w} \]  

(1)

where \( C_w \) and \( C_n \) are the solubility of CA in water and n-octanol, respectively.

2.5. Preparation of CA-NRs and CHS-CA-NRs

Nanoreservoirs were firstly prepared employing Compritol 888 ATO as a sustained release lipid matrix by melt–emulsification–ultrasonication method (Li et al. 2021). Briefly, 500 mg the lipid was blended with CA-ODA conjugate equivalent to 10 mg CA on a heater of 85 °C. Simultaneously, 300 mg Pluronic F-127 in 5 mL deionized water was heated to 85 °C as well. Afterwards, Pluronic F-127 solution was gently added to and homogeneously dispersed with the drug-lipid melt. The obtained coarse hot o/w emulsion was ultrasonicated at 60% amplitude for 15 min using probe sonicator (Bandelin HD 3100, Germany). Finally, CA-NRs were developed by allowing hot nanoemulsion to cool in an ice bath. After that, 500 µL of CHS solution of different concentrations (0.5–5 g%) was mixed with the selected CA-NRs and stirred at 25 °C for 1 h and then stored at 4 °C. Plain nanoparticles were prepared using the same procedure without addition of drug conjugate to the lipid phase or surface functionalization.

2.6. Ca-NRs and CHS-CA-NRs characterization

2.6.1. Particle size (PS), polydispersity index (PDI) and zeta potential (ZP)

PS, PDI and ZP were measured at 25 °C by DLS technique using a Zetasizer (Malvern Instruments Ltd., UK). Dispersions were 40-folds diluted with filtered distilled water. All measurements were performed in triplicate.

2.6.2. Determination of entrapment efficiency (EE%)

EE% was indirectly determined using centrifugal filter tubes (Centricert 1, 100,000 MWCO, Sartorius, Germany) to separate free CA from NRs-associated drug. Then, free CA concentration in the filtrate was spectrophotometrically determined at λ max 258 nm after cooling centrifugation for 15 min at 5000 rpm. EE% was calculated from Equation 2:

\[ EE\% = \frac{\text{Total drug amount} - \text{Free drug amount}}{\text{Total drug amount}} \times 100\% \]  

(2)

2.6.3. Morphological study

CHS-CA-NRs morphology was assessed compared to non-functionalized CA-NRs using TEM (JEM-100S, JOEL Ltd, Japan) after uranyl acetate staining on a carbon-laminated copper grid (Ebada et al. 2021).

2.6.4. Drug release study

Drug release study was implemented using dialysis method. Briefly, 0.5 mL of NRs dispersion was placed into a dialysis bag which was submerged in 15 mL of PBS pH 7.4 at 37 °C in an amber colored glass bottle. The study was executed in triplicates and samples were horizontally shaken at 100 shake/min and 37 °C. Samples (0.5 mL) were withdrawn from the receiver solution at predetermined intervals, replaced with equal volumes of fresh media, and analyzed spectrophotometrically at 258 nm.

2.7. In vivo studies

2.7.1. Animals and osteoarthritis (OA) model

Adult male Wistar rats (200 ± 20 g) procured from the Experimental Animal Center in Faculty of Medicine, Alexandria University were housed 4–5 rats/cage in pathogen free environment. Animals were kept in standard cages at 23–25 °C and 65% relative humidity with a 12 h light/dark cycle and were freely accessed to water and food. Procedures involving animals and their care were followed the handling guidelines published in UK Directive of 1986; 86/609/EEC and the ethical guidelines of Alexandria University on laboratory animals under ethical approval number 062019518254. In all tests, adequate considerations were adopted to reduce pain or discomfort of animals. To induce OA, under 1-3% isoflurane, an IA injection containing 2 mg of monooiodoacetate (MIA) was administered through the infrapatellar ligament into the knee joint space, in 50 µL saline, via a 26.5-G needle (Naveen et al. 2014; Bryk et al. 2021). Control rats were injected with an equivalent volume of saline.
different intervals in healthy or arthritic knee joints following previous report with some modifications (Sacchetti et al. 2014). Briefly, 50 µL of CHS-CA-NRs, CA-NRs and CA suspension containing 100 µg of CA was unilaterally intra-articularly injected into two rat sets in the left knees: the first set composed of healthy Wistar rats (45 male, 200 ± 20 g) and the second set composed of Wistar rats (45 male, 200 ± 20 g) with OA (2 weeks post MIA single injection). The right knees were kept as control. Three rats from each set and each group were sacrificed by cervical dislocation at day 1, 7, 14, 21 and 28 after treatment.

Following sacrifice, knee joints of animals were taken. The femoro-tibial joint of each rat was removed by cutting halfway through the femur and tibia, samples were then fixed in 10% phosphate-buffered formalin and subsequently decalcified in 5% formic acid for 72 h and inserted in paraffin wax. The cartilage sections were imaged under a confocal microscopy (Leica TCS SP SPE II/DMi 8, Wetzlar, Germany) at excitation wavelength (440 nm) and emission wavelength (520 nm). The confocal microscopy pinhole focus = 137.1 µm, the scan speed = 400 Hz in average, the scan mode is unidirectional in the XYZ axes. Imaging was performed by applying both the fluorescent and DIC (differential interference contrast) modes either individually for each fluorochrome or in a merged pattern (Cogswell & Sheppard 1992). Background fluorescence was determined by imaging a cartilage section of control rat joint not injected with CA formulations and subsequently subtracted from each section before quantification of fluorescence. Three images from different parts of each section were analyzed. For fluorescence quantification, confocal microscopy images were analyzed using Image J software (http://ImageJ.nih.gov/ij).

2.7.3. In vivo efficacy study
Male Wistar rats (200 ± 20 g, n = 84) were indiscriminately divided into seven groups. OA was bilaterally induced by single injection of MIA (2 mg/50 µL) in rat knee joints.

Group (1): Normal rats (Negative controls) treated with 50 µL normal saline (n = 12).
Group (2): Arthritic rats (Positive controls) treated with 50 µL normal saline (n = 12).
Group (3): Arthritic rats treated with 50 µL CA suspension (suspended into deionized water containing 0.5% CMC Na) (100 µg CA, n = 12).
Group (4): Arthritic rats treated with 50 µL CA-NRs (F4) (100 µg CA, n = 12).
Group (5): Arthritic rats treated with 50 µL CHS-CA-NRs (F8) (100 µg CA, n = 12).
Group (6): Arthritic rats treated with 50 µL CHS-NRs (CA-free) (250 µg CHS, n = 12).
Group (7): Arthritic rats treated with 50 µL plain NRs (CHS-free, CA-free) (n = 12).

As illustrated in Figure 1, rats were treated with bilateral IA injection of different formulations at the end of week 2 and 5 after MIA injection for OA induction. Rats were sacrificed for analysis after 5 (n = 6) and 8 (n = 6) weeks of OA induction. After the first sacrifice, the harvested joints were subjected to homogenization for biochemical assessment in the joint homogenate. After the second sacrifice, for each rat, one joint was subjected to histological examination and the second joint was subjected to homogenization for biochemical assessment in the joint homogenate.

2.7.3.1. Histological assessment. The femoro-tibial joint of each rat was removed by cutting halfway through the femur and tibia. Tissue samples were prepared for light microscopy using standard procedures (Gerwin et al. 2010). Briefly, samples were fixed in 10% phosphate-buffered formalin and subsequently decalcified in 5% formic acid for 72 h and inserted in paraffin wax. Sections of femoro-tibial joints were routinely processed and stained with H&E (Hematoxylin and Eosin). Additional set of femoro-tibial joints was stained with toluidine blue. Sections were then subjected to histopathological examination under light microscope. Osteoarthritis Research Society International (OARSI) system was followed to estimate the treated tissue deterioration condition for rats sacrificed after 8 weeks of OA induction (Pritzker et al. 2006; Gerwin et al. 2010).

2.7.3.2. Biochemical analysis. Rat joints were homogenized according to previously reported procedure by Janssen et al. (Janssen et al. 2016). Inflammatory cytokine; interleukin-1 beta (IL-1β) and oxidative stress markers; malondialdehyde (MDA) and nitric oxide (NO), matrix metalloproteinase –3 (MMP-3) and aggrecan levels in joint homogenate were estimated as markers of regeneration capacity (dos Santos Duarte Lana & Rodrigues 2019). IL-1β, MMP-3 and aggrecan were determined using commercial enzyme linked immune sorbet assay (ELISA) kits following the manufacturer’s directives (MyBioSource catalog # MBS82501, MBS729026 and MBS721531 respectively). MDA and NO levels were colorimetrically estimated using commercial kits (Biodiagnostic, Egypt) following the manufacturer’s protocol.

2.7.3.3. Statistical analysis. Statistics of the in vitro studies results were accomplished using Student’s t-test with significance level at p < .05 (GraphPad Prism 6, USA). Statistical
analysis for in vivo studies results was done using SPSS 20 (SPSS, Chicago. IL). The results were analyzed statistically by one-way analysis of variance ANOVA, followed by a Post Hoc (Tukey) test to compare variables between different groups. Statistical significance was set at \( p < .05 \). Values were expressed as mean ± SD.

3. Results and discussion

CA low oral bioavailability along with substantial side effects resulted in unmet clinical need for OA therapy. Thus, in our previous work, the local transdermal route was exploited to deliver CA to the arthritic joint, which has proven significant amelioration in cartilage degeneration, overcoming low bioavailability and side effects (Ebada et al. 2021). Herein, for the first time, cartilage-targeted nanocarriers loaded with chondroprotective CA were tailored and functionalized with CHS for IA injection and evaluated versus non-functionalized ones. Given that cartilage tissue is the primary site affected by OA and it is CAs’ target, the effectiveness of different cartilage-targeting strategies was evaluated according to cartilage biodistribution and retention, and the extent of these outcomes on OA repair was assessed. Moreover, solid lipid-based nanoparticles were employed as potential carriers for sustained drug release as they offer several advantages: first, they are composed of safe, biocompatible and biodegradable ingredients. Besides, their surface can be functionalized with target-specific ligands (Gad et al. 2022). Additionally, for their preparation neither organic solvents nor expensive excipients are needed as in the case of polymeric nanoparticles (Paliwal et al. 2020). One of the crucial factors to develop appropriate lipid nanosystems with good drug loading capacity and sustained release, is the drug lipid solubility. However, upon screening different lipids for solubilization, CA exhibited poor lipid solubility where 5 mg CA needed >5 g of lipid for CA solubilization. This observation was harmonious with CA physicochemical properties as CA shows poor solubility in highly hydrophobic solvents (Cheng et al. 2015).

3.1. Preparation and characterization of CA-ODA conjugate

For modifying CA lipophilicity without chemical alteration, octadecylamine (ODA) was selected as a lipophilic primary alkyl amine to develop a lipophilic form of CA based on ionic conjugation. The chemical structures of CA and ODA were depicted in Figure 2(a). CA-ODA conjugates formation were verified by FTIR and partition coefficient. FTIR spectra of CA-ODA conjugates manifested an absence of CA peak at 1680 cm\(^{-1}\) which was corresponding to C=O stretch of COOH group as illustrated in Figure 2(b). Additionally, the peak of amine group of ODA (3328 cm\(^{-1}\)) has been diminished in the developed CA-ODA conjugate. Changes in the FTIR spectroscopy indicated the interaction between the amine group of ODA and the carboxyl group of CA, and confirming the formation of CA-ODA conjugate (Jalil et al. 2020; Rodrigues et al. 2020). Additionally, for partition coefficient, compared to CA, CA-ODA conjugates exhibited significant improvement in lipophilicity (Figure 2(c)). In particular, CA-ODA conjugate 1:3 showed high significant improvement (\( p < .0001 \)) where \( \frac{P_{/w}}{C_0} \) value was approximately 296 times greater than that of CA (\( \frac{P_{/w}}{C_0} = 2.26 ± 0.087 \)) confirming the higher lipophilic attribute of CA-ODA conjugate 1:3.

FTIR results and the enhanced oil/water partition could be explained by the electrostatic interaction between CA and ODA that masked their polar groups in addition to the long fatty acid chain of the ODA.

3.2. Preparation and characterization of CA-NRs and CHS-CA-NRs

Given CA physicochemical properties, tailoring of lipid NRs loaded with free CA was handicapped by its poor lipophilicity, higher melting point and low drug solubility in most organic solvents which hindered their use during preparation. Therefore, the developed lipophilic CA-ODA conjugates were incorporated into Compritol ATO 888 lipid matrix to develop CA-NRs and afterwards the selected NRs was functionalized with CHS using serial CHS concentrations. CA-NRs loaded with CA-ODA 1:3 conjugate was selected to be functionalized with CHS based on its high drug encapsulation efficiency, controlled release, high positive surface charge that enable functionalization. Composition and characterization of the developed NRs were summarized in Supplemental Table 1.

3.2.1. Particle size (PS), polydispersity index (PDI) and zeta potential (ZP)

The developed NRs laid into the nano-range, as illustrated in Supplemental Table 1. Moreover, there was a gradual increase in PS and PDI together with a corresponding increase in CHS concentration which might be imputed to heterogeneous attachment of CHS on the NRs surface and partial neutralization of the surface charge leading to some particles aggregation. Further increase in CHS concentration resulted in smaller particle size with narrow particles distribution at 0.5% CHS concentration where PS and PDI of CHS were 156.80 ± 0.05 nm and 0.27 ± 0.01, respectively. This decrease in PS and PDI values might be imputed to the homogenous distribution of CHS on the NRs surface and also might be most probably explained from the ZP values where the uniform layer of CHS deposited on NRs surface led to high repulsion between particles resulting in particle size decrease.

For the ZP values of CA-NRs, ODA (octadecylamine) altered particles ZP to positive sign compared to ZP of plain NRs (−13.82 ± 0.07 mV) as manifested in Supplemental Table 1. So incorporation of ODA provided CA with the desired lipophilicity to be properly loaded into the NRs lipid matrix and excess ODA acts as surface charge modifier yielding CA-NRs bearing highly positive surface (Castro et al. 2009). Therefore, CA-NRs loaded CA-ODA 1:3 (F4) showed the highly positive charged nanoparticles (ZP= 41.83 ± 5.63 mV). For CHS-RA-NRs, Supplemental Table 1 illustrated the progressive decrease in ZP values with CHS concentration increasing,
confirming the attachment of negatively charged CHS to the positively charged NRs surface. The final highly negative values after the last two CHS additions (0.5 and 1 g%) (−28.3 ± 6 mV, −30.5 ± 4.03 mV, respectively) affirmed the CHS shell existence on CA-NRs surface, this negative charge might arise from the ionized groups of chondroitin sulfate molecules (Luo et al. 2021).

3.2.2. Entrapment efficiency (EE%)
Herein, incorporation of CA-ODA conjugate during NRs preparation enabled CA encapsulation into lipid systems with excellent EE% (99.87 ± 0.23%), as illustrated in supplemental Table 1. This higher EE% might be explained by higher lipid partitioning of CA-ODA conjugate into the lipid matrix. This finding was harmonious with other works that improved the encapsulation of adapalene and breviscapine into lipid nanoparticles based on ionic conjugation with ODA (Li et al. 2013; Jalil et al. 2020).

Upon CHS functionalization, NRs exhibited good EE% ranging from 89.82 ± 0.32% to 99 ± 0.34%. A progressive decrease in EE% was observed upon increasing the CHS conc. which could be explained as follow: as the amount of the added CHS increased, CHS not only interact with the deposited ODA but also compete with CA for ODA involved in CA-ODA conjugate resulting in a slight dissociation in CA-ODA conjugate expelling free CA out of the lipid matrix. This observation might be imputed to the highly negative charge density of CHS (−2) compared to CA (−1) at neutral pH.

Here, this study compared between two different targeting approaches; active targeting using CHS and passive targeting governed with electrostatic interaction between positively charged CA-NRs and negatively charged cartilage matrix components (GAGs) to evaluate the optimal approach in OA therapy. Therefore, F4 and F8 were selected as promising passive and active cartilage-targeted NRs, respectively, based on their surface charge, good EE%, acceptable PS and PDI.

3.2.3. Morphological study
In Figure 2(d), TEM image of CHS-CA-NRs (F8) showed spherical, well dispersed and separated nanoparticles with clear deposited dark layer at the surface confirming efficient coating of NRs with CHS. While TEM image of non-functionalized CA-NRs (F4) showed nanoparticles with smooth morphology.

3.2.4. Drug release studies
In Figure 2(e), CA release rate from F8 (CHS-CA-NRs) and F4 (CA-NRs) was significantly slower than that from CA
suspension. Ionic-conjugate integrated NRs exhibited biphasic profile with an initial rapid release followed by a sustained slower phase, releasing about 70% of CA over 13 day.

### 3.3. In vivo evaluation

In OA animal model, single IA injection of MIA has been vastly used to suppress aerobic glycolysis resulting in chondrocytes death and cartilage structural changes which resemble to OA progress in human (Bryk et al. 2021).

#### 3.3.1. Cartilage-targeting ability and retention time assessment

Cartilage-targeting capability and retention time of different CA formulations in the articular cartilage, as OA hallmark and site of action of CA, was investigated in healthy and OA-bearing rats by trafficking fluorescence under confocal microscope. In this study, rats were intra-articularly injected at day 0 and the joints were harvested at day 1, 7, 14, 21 and 28 post injection, and the cartilages were cut into sections to be observed under a confocal microscope.

The cartilage treated with CHS-CA-NRs, either healthy or arthritic groups, revealed the strongest fluorescent green signals (Figure 3(a)). CHS-CA-NRs showed a highly significant increase in fluorescence intensity (210 ± 40 and 170 ± 25 for healthy and arthritic groups, respectively) compared to CA suspension (55 ± 10 and 40 ± 7 for healthy and arthritic groups, respectively) (p < .001) after day 1 (Figure 3(b)).

Additionally, CHS coating weighed super-fluorescence intensities over that was governed by the electrostatic interaction between positively charged CA-NRs and highly negatively charged cartilage matrix (Figure 3(b)).

Regarding intra-chondrocytes delivery, amid the arthritic groups, the highest fluorescent signals were detected with CHS-CA-NRs at 7 days post injection, and decreased until 21 days (Figure 4). Meanwhile, for CA-NRs, only mild fluorescent signals were detected inside the chondrocytes at 7 days of injection. This result suggested that CHS-CA-NRs specifically facilitated CA delivery and retention in the cartilage and maintained high local concentration in the cartilage for 21 days from injection. These results declared that CHS enabled the nanoparticles to sneak into the cartilage matrix through its nature as a main component of the cartilage matrix. These findings were congruent with previous in vitro, ex vivo and in vivo studies that reported the specific uptake of CHS in human articular cartilage which was most probably due to interaction with CoI2 and CD36 and other receptors on chondrocytes, which possess a high affinity for CHS (Sobal et al. 2008, 2013, 2016).

Herein, OA pathology non-significantly affected the distribution profile of intra-articularly CA formulations within the cartilage sections. Nevertheless, in general healthy groups showed more fluorescence compared to arthritic groups at the same time interval for the same formula however the fluorescence of CHS-CA-NRs > CA-NRs > CA suspension. These findings were harmonious with Sacchetti et al. (Sacchetti et al. 2014), while they disagreed with other studies that revealed that arthritis pathological features might

---

![Figure 3](image-url)

**Figure 3.** Confocal laser microscopy photos for articular cartilage following single intra-articular injection of different CA formulations containing 100 μg CA/50 μL into the healthy and arthritic knee joints of rats, the fluorescence distribution was observed at day 1, 7, 14, 21 and 28 after administration, magnification × 10 (a). The relative mean fluorescence intensities were determined in articular cartilage of different groups at day 1, 7, 14, 21 and 28 after administration and shown as mean ± SD (n = 3) (b).
3.3.2. In vivo efficacy study

3.3.2.1. Histological assessment. Histological examination of H&E stained femoro-tibial joint sections in different treated groups at the end of week 8 after OA induction revealed an improvement of cartilage histopathological features in CA-treated groups frustrating the extensive cartilage degeneration Figure 5(a–j). Interestingly, the progression of OA was ameliorated at the greatest level in CHS-CA-NRs group, as evidenced by reduced cartilage degradation (Figure 5(i,j)), more toluidine staining (Figure 5(s)), and the lowest OARSI score (2 ± 1.5) among the treated groups with OA showing non-significant difference compared to normal group (p = 0.3962) (Figure 6). While CA-NRs showed higher significant inhibition in inflammatory level compared to CA suspension and CHS-NRs (p = 0.0039 and p = 0.0306, respectively at 8 weeks interval), it exhibited significant lower anti-inflammatory effect compared to CHS-CA-NRs (p = 0.0189). These results indicated the accelerated anti-inflammatory effect of CA in presence of CHS in OA rats.

3.3.2.2. Biochemical analysis.

3.3.2.2.1. Assessment of inflammatory cytokines (IL-1β). At 5 and 8 weeks intervals, the most significant improvement was observed in CHS-CA-NRs treated group (Figure 7(a)) which reached at 8 weeks interval to a non-significant inflammatory level compared to the normal control level [p = 0.9047]. While CA-NRs showed higher significant inhibition in inflammatory level compared to CA suspension and CHS-NRs (p = 0.0039 and p = 0.0306, respectively at 8 weeks interval), it exhibited significant lower anti-inflammatory effect compared to CHS-CA-NRs (p = 0.0189). These results indicated the accelerated anti-inflammatory effect of CA in presence of CHS in OA rats.

3.3.2.2.2. Assessment of oxidative stress. The effect of different studied intra-articular formulations on knee homogenate levels of two different oxidative stress markers (malondialdehyde (MDA) and nitric oxide (NO)) was investigated. As seen in Figure 7(b), statistically significant lower levels of MDA were obtained when arthritic rats received intra-articular CA formulations where CHS-CA-NRs manifested the highest antioxidant activity reaching MDA expression close to the normal control level at the end of week 8 interval after OA induction (9.8 ± 0.17 and 9.6 ± 0.0 nmol/mL, respectively). For CHS-NRs, an initially highest significant decrease in MDA level at 5 weeks interval (15.8 ± 1.06 nmol/mL) was observed.
compared to OA group and almost maintained at 8 weeks interval (16.9 ± 3.74 nmol/mL).

Nitric oxide (NO) is a disruptive agent responsible for OA process progress by mediating the expression of inflammatory cytokines, which inhibits the synthesis of collagen and proteoglycans. The expression of NO was markedly increased in OA articular cartilage and synovium (Leonidou et al. 2018). In the present study, NO level was measured at the end of the experiment period to assess the progress in oxidative stress in joint region.

Figure 7(c) depicted the significant reduction in NO level for all CA treated groups compared to CHS-NRs and plain NRs groups exploiting the potential antioxidant activity of CA in in vivo OA model. Meanwhile, CHS-CA-NRs group showed the highest suppressing effect compared to CA-NRs and CA suspension groups where NO levels were 52.63 ± 9.26, 73.36 ± 11.21 and 78.86 ± 11.50 μM, respectively.

3.3.2.2.3. Assessment of cartilage degradation/synthesis. Regarding aggrecan joint homogenate level as shown in Figure 7(d), the mean level was significantly decreased in OA group compared to the normal control group, while it was significantly increased in all treated groups compared to OA group at 8 weeks interval. CHS-CA-NRs showed the highest elevation in aggrecan level exhibiting significant improvement compared to either CA-NRs ($p = .0471$ and $p = .0071$ at 5 and 8 week intervals, respectively) or CHS-NRs ($p < .0001$ at both intervals).

For MMP-3 level in joint homogenate (Figure 7(e)), CHS-CA-NRs were capable of significantly decreasing the levels of MMP-3 produced by chondrocytes compared to OA group level and all other treated groups ($p < .0001$ compared to CA-susp and CHS-NRs) ($p = .0354$ compared to CA-NRs). These results suggested the potential synergistic antiosteoarthritic effect of CA in presence of CHS.

Amid the groups treated with different CA formulations, CHS-CA-NRs group revealed the most brilliant improvement in both histological and biochemical evaluation parameters. These findings proved the impact of targeting the articular cartilage along with CHS which may be imputed to a synergistic effect by dual mechanism of action on the pathology of degenerative cartilage and/or to the ability of CHS to accelerate the retention of highest amount of CA as previously confirmed by the highest fluorescence observed within the articular cartilage and inside chondrocytes also. CHS coat resulted in evident cartilage regeneration more than this observed in case of CA-NRs as its positively charged surface enabled prolonged retention of CA within the negatively charged matrix however histopathological photos of arthritic cartilage showed depleted areas of matrix and lowest toluidine blue staining confirming the depletion of highly negatively charged GAGs and thus lowering the targeting efficiency. These results were harmonious with other studies that achieved great success in OA therapy capitalizing the cartilage targeting potential of CHS (Bishnoi et al. 2014; Jain et al. 2014; Yin et al. 2017).

While the proven CHS protecting benefits for cartilage and its ability to preferentially enter the cartilage tissue to relieve OA symptoms (Pelletier et al. 2016), the group treated with CHS-NRs showed only 40% decrease in OARSI score which might be imputed to the slow onset of CHS action where its clinical effect appear after about 3-6 months (Bian et al. 2009). Therefore, a prophylactic treatment against the progression of joint degeneration in OA might be most beneficial (Basalo et al. 2007; Fernández-Martín et al. 2021).

It is worth mentioned that IA injection of CHS-CA-NRs could decrease OARSI score by 90% using only 200 µg/joint over 6 weeks treatment. However, an IA injection of DCN loaded nanoparticles (500 µg/joint) offer 64% reduction in OARSI score after 8 weeks treatment (Jung et al. 2020). Herein, These results declared that cartilage-targeted delivery along with CHS has a great potential success on the delivery of natural antiosteoarthritic drug for local OA therapy.
4. Conclusion

In this work, this is the first comparison between active and passive cartilage-targeting strategies using chondroitin sulfate coated nanoreservoirs (CHS-CA-NRs) and cationic nanoreservoirs (CA-NRs), respectively, for optimal OA therapy through IA delivery of castic acid (CA). Cationic CA-NRs were prepared capitalizing ionic conjugation approach to improve drug encapsulation, extend drug release and alter nanoparticles surface charge into positive charge for targeting purpose and CHS functionalization. Active targeted CHS-CA-NRs showed the superior articular cartilage targeting capability lasting for 21 days in proximity to and inside chondrocytes. Moreover, CHS-CA-NRs showed the highest amelioration of cartilage structural alterations with the lowest OARSI score in arthritic rats. Therefore, CHS-CA-NRs hold promises for OA therapy.
Acknowledgements

Authors would like to acknowledge Dr. Hoda Khalifa and Dr. Amany Soliman for their collaboration in histopathological examination.

Disclosure statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Data availability statement

Data supporting the study findings are available from the corresponding author on request.

References

Allam AN, Hamdallah SI, Abdallah OY. (2017). Chitosan-coated diacerein nanosuspensions as a platform for enhancing bioavailability and lowering side effects: preparation, characterization, and ex vivo/in vivo evaluation. Int J Nanomedicine 12:4733–45.

Almezgafi M, Zhang Y, Hezam K, et al. (2020). Diacerein: recent insight into pharmacological activities and molecular pathways. Biomed Pharmacother 131:110594.

Asfour MH, Kassem AA, Salama A, Abd El-Alim SH. (2020). Hydrophobic ion pair loaded self-emulsifying drug delivery system (SEDDS): a novel oral drug delivery approach of cromolyn sodium for management of bronchial asthma. Int J Pharm 585:119494.

Basalo IM, Chahine NO, Kaplun M, et al. (2007). Chondroitin sulfate reduces the friction coefficient of articular cartilage. J Biomech 40: 1847–54.

Bashyal S, Seo J-E, Choi YW, Lee S. (2021). Bile acid transporter-mediated oral absorption of insulin via hydrophobic ion-pairing approach. J Control Release 338:644–61.

Bedingfield SK, Colazo JM, Yu F, et al. (2021). Amelioration of post-traumatic osteoarthritis via nanoparticle depots delivering small interfering RNA to damaged cartilage. Nat Biomed Eng 5:1065–1069.

Bian L, Kaplun M, Williams DY, et al. (2009). Influence of chondroitin sulfate on the biochemical, mechanical and frictional properties of cartilage explants in long-term culture. J Biomech 42:286–90.

Bishnoi M, Jain A, Hurkat P, Jain SK. (2014). Aceclofenac-loaded chondroitin sulfate conjugated SLNs for effective management of osteoarthritis. J Drug Target 22:805–12.

Boileau C, Tat SK, Pelletier J-P, et al. (2008). Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodelling. Arthritis Res Ther 10:871.

Brown S, Kumar S, Sharma B. (2019). Intra-articular targeting of nanomaterials for the treatment of osteoarthritis. Acta Biomater 93:239–57.

Brown SB, Wang L, Jungels RR, Sharma B. (2020). Effects of cartilage-targeting moieties on nanoparticle biodistribution in healthy and osteoarthritic joints. Acta Biomater 101:469–83.

Bryk M, Chwastek J, Mliost J, et al. (2021). Sodium monooiodoacetate dose-dependent changes in matrix metalloproteinases and inflammatory components as prognostic factors for the progression of osteoarthritis. Front Pharmacol 12:643605.

Castro GA, Coelho ALLR, Oliveira CA, et al. (2009). Formation of ion pairing as an alternative to improve encapsulation and stability and to reduce skin irritation of retinoic acid loaded in solid lipid nanoparticles. Int J Pharm 381:77–83.

Cheng Y, Wang D, Zhang Z, Wang Z. (2015). Solubility and solution thermodynamics of rhein in eight pure solvents from (288.15 to 313.15) K. RSC Adv 5:80548–52.

Coggswell CJ, Sheppard CJR. (1992). Confocal differential interference contrast (DIC) microscopy: including a theoretical analysis of conventional and confocal DIC imaging. J Microsc 165:81–101.

dos Santos Duarte Lana JF, Rodrigues BL. (2019). Osteoarthritis as a chronic inflammatory disease: a review of the inflammatory markers. In: Osteoarthritis biomarkers and treatments. London: IntechOpen.

Ebada HMK, Nasra MMA, Elnaggar YSR, Abdallah OY. (2021). Novel rhein–phospholipid complex targeting skin diseases: development, in vitro, ex vivo, and in vivo studies. Drug Deliv Transl Res 11:1107–18.

Ebada HMK, Nasra MMA, Elnaggar YSR, et al. (2021). Novel rhein integrate transphytosomes as non-invasive local therapy for osteoarthritis to ameliorate cartilage deterioration in MIA-arthritis rats. Colloids Surf B Biointerfaces 202:111713.

Eladawy NO, Morsi NW, Shamma RN. (2021). Diacerein-loaded hyalurons as a dual-function platform for osteoarthritis management via intra-articular injection: in vitro characterization and in vivo assessment in a rat model. Pharmaceutics 13:765.

Feng H, Zhu Y, Fu Z, Li D. (2017). Preparation, characterization, and in vivo study of rhein solid lipid nanoparticles for oral delivery. Chem Biol Drug Des 90:867–72.

Fernández-Martín S, González-Cantalapiedra A, Muñoz F, et al. (2021). Glucosamine and chondroitin sulfate: is there any scientific evidence for their effectiveness as disease-modifying drugs in knee osteoarthritis preclinical studies?—A systematic review from 2000 to 2021. Animals 11:1608.

Gad HA, Elezaby RS, Mansour M, Hathout RM. (2022). Novel approaches of solid lipid nanoparticles as drug carrier. Nanoenng Biomater Drug Deliv 1:107–43.

Gerwin N, Bendele AM, Glasson S, Carlson CS. (2010). The OARSI histopathology initiative – recommendations for histological assessments of osteoarthritis in the rat. Osteoarthr Cartilage 18:S24–S34.

Gómez-Gaete C, Ferreira F, Bustos P, et al. (2018). Optimization of rhein-loaded polymeric nanoparticles using a factorial design and evaluation of the cytotoxic and anti-inflammatory effects. Drug Dev Ind Pharm 44:1285–94.

Gómez-Gaete C, Retamal M, Chávez C, et al. (2017). Development, characterization and in vitro evaluation of biodegradable rhein-loaded microparticles for treatment of osteoarthritis. Eur J Pharm Sci 96:390–7.

Gu X, Zheng Y. (2015). Preparation, characterization, and in vivo study of rhein-loaded poly(Lactic-co-glycolic acid) nanoparticles for oral delivery, Drug Design. Drug Des Devel Ther 9:2301–9.

He K, Huang X, Shan R, et al. (2022). Intra-articular injection of lornoxicam and microRNA-140 co-loaded cationic liposomes enhanced the therapeutic treatment of experimental osteoarthritis. AAPS PharmSciTech 23:1–17.

Hu B, Gao F, Li C, et al. (2020). Rhein laden pH-responsive polymeric nanoparticles for treatment of osteoarthritis. AMB Express 10:158.

Ismail R, Phan TNO, Laffleur F, et al. (2020). Hydrophobic ion pairing of a GLP-1 analogue for incorporating into lipid nanocarriers designed for oral delivery. Eur J Pharm Biopharm 152:10–7.

Jain A, Mishra SK, Vuddanda PR, et al. (2014). Targeting of diacerein loaded lipid nanoparticles to intra-articular cartilage using chondroitin sulfate as homing carrier for treatment of osteoarthritis in rats. Nanomedicine 10:e1031–S34.

Jain A, Singh S, Singh Y, Singh S. (2013). Development of lipid nanoparticles of diacerein, an antiosteoarthritis drug for enhancement in bioavailability and reduction in its side effects. J Biomed Nanotechnol 9:891–900.

Jalil A, Asim MH, Nazir I, et al. (2020). Self-emulsifying drug delivery systems containing hydrophobic ion pairs of polymyxin B and agamic acid: a decisive strategy for enhanced antimicrobial activity. J Mol Liq 311:113298.

Jansen MP, Mastbergen SC. (2022). Joint distraction for osteoarthritis: clinical evidence and molecular mechanisms. Nat Rev Rheumatol 18:35–46.
Janssen M, Timur UT, Wokie N, et al. (2016). Celecoxib-loaded PEA microspheres as an auto regulatory drug-delivery system after intra-articular injection. J Control Release 244:30–40.

Jung JH, Kim SE, Kim H-J, et al. (2020). A comparative pilot study of oral diacerein and locally treated diacerein-loaded nanoparticles in a model of osteoarthritis. Int J Pharm 581:119249.

Kaur A, Bhoop BS, Chhibber S, et al. (2017). Supramolecular nano-engineered lipidic carriers based on difunisal-phospholipid complex for transdermal delivery: QbD based optimization, characterization and preclinical investigations for management of rheumatoid arthritis. Int J Pharm 533:206–24.

Latourte A, Kloppenburg M, Richette P. (2020). Emerging pharmaceutical therapies for osteoarthritis. Nat Rev Rheumatol 16:673–88.

Lawson TB, Makela JTA, Klein T, et al. (2021). Nanotechnology and osteoarthritis. Part 2: opportunities for advanced devices and therapeutics. J Orthop Res 39:473–84.

Leonidou A, Lepetsos P, Mintzas M, et al. (2018). Inducible nitric oxide synthase as a target for osteoarthritis treatment. Expert Opin Ther Targets 22:299–318.

Li G, Lee WJ, Tan CP, et al. (2021). Tailored rigidity of W/O Pickering emulsions using diacylglycerol-based surface-active solid lipid nanoparticles. Food Funct 12:11732–46.

Li G-M, Chen J-R, Zhang H-Q, et al. (2021). Update on pharmacological activities, security, and pharmacokinetics of rhein. Evid Based Complement Alternat Med 2021:4582412. (i).

Li M, Zheng Y, Shan FY, et al. (2013). Development of ion-complex-based nanostructured lipid carriers to improve the pharmacokinetic profiles of brevicacline. Acta Pharmacol Sin 34:1108–15.

Liang Y, Xu X, Xu L, et al. (2021). Non-surgical osteoarthritis therapy, intra-articular drug delivery towards clinical applications. J Drug Target 29:609–16.

Luo J, Zhang Z, Zeng Y, et al. (2021). Co-encapsulation of collagenase type I and sildinin in chondroitin sulfate coated multilayered nanoparticles for targeted treatment of liver fibrosis. Carbohydr Polym 263:117964.

Malkawi A, Jall A, Nazir I, et al. (2020). Self-emulsifying drug delivery systems: hydrophobic drug polymer complexes provide a sustained release in vitro. Mol Pharmaceutics 17:3709–19.

Maneche Castro LM, Garcia AJ, Guldberg RE. (2021). Biomaterial strategies for improved intra-articular drug delivery. J Biomed Mater Res A 109:426–36.

Martin G, Bogdanowicz P, Domagala F, et al. (2003). Rhein inhibits interleukin-1β-induced activation of MEK/ERK pathway and DNA binding of NF-xB and AP-1 in chondrocytes cultured in hypoxia: a potential mechanism for its disease-modifying effect in osteoarthritis. Inflammation 27:233–46.

Maudens P, Jordan O, Allémand E. (2018). Recent advances in intra-articular drug delivery systems for osteoarthritis therapy. Drug Discovery Today 23:1761–75.

Migliore A, Paolletta M, Moretti A, et al. (2020). The perspectives of intra-articular therapy in the management of osteoarthritis. Expert Opin Drug Deliv 17:1213–26.

Moldovan F, Pelletier J, Jolicoeur FC, et al. (2000). Diacerein and rhein reduce the ICE-induced IL-1β and IL-18 activation in human osteoarthritic cartilage. Osteoarthritis and Cartilage 8:186–96.

Morales M, Irlandini E. (2022). Conservative treatments of osteochondral lesions of the knee. In: Gobbi A, Lane JG, Longo UG, Dallo I, eds. Joint function preservation: a focus on the osteochondral unit. Cham: Springer International Publishing, 375–87.

Naveen SV, Ahmad RE, Hui WJ, et al. (2014). Histology, glycosaminoglycan level and cartilage stiffness in mononiodoacetate-induced osteoarthritis: comparative analysis with anterior cruciate ligament transection in rat model and human osteoarthritis. Int J Med Sci 11:97–105.

Paliwal R, Paliwal SR, Kenwatt R, et al. (2020). Solid lipid nanoparticles: a review on recent perspectives and patents. Expert Opin Ther Pat 30:179–94.

Pelletier J-P, Raynauld J-P, Beaulieu AD, et al. (2016). Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Res Ther 18:256.

Peng Z, Sun H, Bunpetch V, et al. (2021). The regulation of cartilage extracellular matrix homeostasis in joint cartilage degeneration and regeneration. Biomaterials 268:120555.

Petrailo S, Zanardi I, Memoli A, et al. (2009). Solubility, spectroscopic properties and photostability of Rhein/cyclodextrin inclusion complex. Spectrochim Acta A Mol Biomol Spectrosc 74:1254–9.

Pradl J, Maidens P, Gabay C, et al. (2016). Effect of particle size on the biodistribution of nano- and microparticles following intra-articular injection in mice. Int J Pharm 498:119–29.

Pritzker KPH, Gay S, Jimenez SA, et al. (2006). Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage 14:13–29.

Rabei M, Kashanian S, Samavati SS, et al. (2021). Nanotechnology application in drug delivery to osteoarthritis (OA), rheumatoid arthritis (RA), and osteoporosis (OSP). J Drug Delivery Sci Technol 61:102011.

Reginster J-Y, Veronese N. (2021). Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment. Aging Clin Exp Res 33:37–11.

Ristrop K, Salim M, Wilson BK, et al. (2021). Internal liquid crystal structures in nanocarriers containing drug hydrophobic ions pairs dictate drug release. J Colloid Interface Sci 582:815–24.

Rodrigues LBO, Lima FA, Alves CPB, et al. (2020). Ion pair strategy in solid lipid nanoparticles: a targeted approach to improve epidural targeting with controlled adapalene release, resulting reduced skin irritation. Pharm Res 37:148.

Sacchetti C, Liu-Bryan R, Magrini A, et al. (2014). Polyethylene-glycol-modified single-walled carbon nanotubes for intra-articular delivery to chondrocytes. ACS Nano 8:12280–91.

Schöngen RN, Giannetti BM, van de Leur E, et al. (1988). Effect of diacetylrhein on the phagocytosis of polymorphonuclear leucocytes and its influence on the biosynthesis of hyaluronate in synovial cells. Arzneimittelfororsch 38:744–8.

Sobal G, Dorotka R, Menzel J, Sinzinger H. (2013). Uptake studies with chondroitropic 99mTc-chondroitin sulfate in articular cartilage. Implications for imaging osteoarthritis in the knee. Nucl Med Biol 40:1013–7.

Sobal G, Menzel EJ, Sinzinger H. (2008). Radiolabeling procedure, quality control and stability of 99mTc-labeled chondroitin sulfate: a new approach of targeting osteoarthritis. Appl Radiat Isot 66:415–20.

Sobal G, Velusamy K, Kosik S, et al. (2016). Preclinical evaluation of (99m)Tc labeled chondroitin sulfate for monitoring of cartilage degeneration in osteoarthritis. Nucl Med Biol 43:339–46.

Sun H, Luo G, Chen D, Xiang Z. (2016). A comprehensive and system review for the pharmacological mechanism of action of rhein, an active anthraquinone ingredient. Front Pharmacol 7:247.

van den Bosch MHJ. (2021). Osteoarthritis year in review 2020: biology. Osteoarthritis and Cartilage 29:143–50.

Wang H, Yang D, Li L, et al. (2020). Anti-inflammatory Effects and Mechanisms of Rhein, an Anthraquinone Compound, and Its Applications in Treating Arthritis: A Review. Nat Prod Bioprospect 10:20–46.

Xiao S, Lin Y, Tang Y, et al. (2021). Real-time quantification of cartilage degeneration by GAG-targeted cationic nanoparticles for efficient therapeutic monitoring in living mice. Mol Pharm 18:1444–54.

Yin X-f, Wang L-l, Chu X-c. (2017). A novel chondroitin sulfate decorated nano platinum for the treatment of osteoarthritis. Mater Sci Eng C Mater Sci Biol Appl 78:452–6.